Prenetics Global (PRE) Stock Overview
Operates as a consumer health sciences company in the United States and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PRE Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Prenetics Global Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.08 |
| 52 Week High | US$27.24 |
| 52 Week Low | US$9.28 |
| Beta | 0.31 |
| 1 Month Change | 16.86% |
| 3 Month Change | 16.24% |
| 1 Year Change | 143.20% |
| 3 Year Change | 216.60% |
| 5 Year Change | -79.83% |
| Change since IPO | -80.21% |
Recent News & Updates
Recent updates
Prenetics Global: Marketing Mastery The Key To Robust Revenue Growth
Summary Prenetics Global Limited has achieved explosive growth, reaching 140,000 subscriptions in 20 months, driven by its IM8 supplement and AI-powered marketing. One of the keys to this growth is its marketing mastery, using A/B and multivariate testing to quickly identify the most effective advertising messages. A unique deal with General Catalyst enables PRE to finance up to 70% of customer acquisition costs without equity dilution or debt, amplifying marketing leverage. I maintain a Strong Buy rating, targeting $37.00 per share, reflecting PRE's robust growth, transition to profitability, and superior marketing execution. Read the full article on Seeking Alpha
PRE: Inter Miami Partnership Will Drive Future Revenue And Brand Upside
Analysts have raised their fair value estimate for Prenetics Global from $31.00 to $34.20. This change reflects updated assumptions regarding discount rates, revenue growth, profit margins and a higher future P/E multiple in their valuation analysis.Prenetics Global Limited's (NASDAQ:PRE) P/S Is Still On The Mark Following 30% Share Price Bounce
Despite an already strong run, Prenetics Global Limited ( NASDAQ:PRE ) shares have been powering on, with a gain of 30...Market Participants Recognise Prenetics Global Limited's (NASDAQ:PRE) Revenues Pushing Shares 27% Higher
Prenetics Global Limited ( NASDAQ:PRE ) shares have had a really impressive month, gaining 27% after a shaky period...Prenetics Global Limited's (NASDAQ:PRE) P/S Is Still On The Mark Following 50% Share Price Bounce
Prenetics Global Limited ( NASDAQ:PRE ) shares have had a really impressive month, gaining 50% after a shaky period...What You Can Learn From Prenetics Global Limited's (NASDAQ:PRE) P/S After Its 27% Share Price Crash
To the annoyance of some shareholders, Prenetics Global Limited ( NASDAQ:PRE ) shares are down a considerable 27% in...Prenetics Global Limited's (NASDAQ:PRE) P/S Is Still On The Mark Following 32% Share Price Bounce
Prenetics Global Limited ( NASDAQ:PRE ) shareholders have had their patience rewarded with a 32% share price jump in...Prenetics Global Limited's (NASDAQ:PRE) Earnings Haven't Escaped The Attention Of Investors
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Prenetics Global Limited (NASDAQ:PRE) Looks Just Right With A 29% Price Jump
Prenetics Global Limited ( NASDAQ:PRE ) shareholders would be excited to see that the share price has had a great...Prenetics Global Limited's (NASDAQ:PRE) 36% Cheaper Price Remains In Tune With Revenues
The Prenetics Global Limited ( NASDAQ:PRE ) share price has fared very poorly over the last month, falling by a...Prenetics Global Limited (NASDAQ:PRE) Held Back By Insufficient Growth Even After Shares Climb 30%
Prenetics Global Limited ( NASDAQ:PRE ) shareholders are no doubt pleased to see that the share price has bounced 30...Prenetics Global GAAP EPS of -$2.91, revenue of $51.72M
Prenetics Global press release (NASDAQ:PRE): Q2 GAAP EPS of -$2.91. Revenue of $51.72M (-34.5% Y/Y). Adjusted EBITDA of $6.5M Raises full year adjusted EBITDA guidance to the range of US$35 million to US$45 million, with corresponding full year revenue guidance in the range of US$255 million to US$275 millionShareholder Returns
| PRE | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -9.9% | -0.4% | -1.5% |
| 1Y | 143.2% | 19.3% | 13.3% |
Return vs Industry: PRE exceeded the US Healthcare industry which returned 19.3% over the past year.
Return vs Market: PRE exceeded the US Market which returned 13.3% over the past year.
Price Volatility
| PRE volatility | |
|---|---|
| PRE Average Weekly Movement | 11.0% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PRE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRE's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 98 | Danny Yeung | www.prenetics.com |
Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories.
Prenetics Global Limited Fundamentals Summary
| PRE fundamental statistics | |
|---|---|
| Market cap | US$408.54m |
| Earnings (TTM) | -US$55.98m |
| Revenue (TTM) | US$154.59m |
Is PRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRE income statement (TTM) | |
|---|---|
| Revenue | US$154.59m |
| Cost of Revenue | US$65.29m |
| Gross Profit | US$89.30m |
| Other Expenses | US$145.28m |
| Earnings | -US$55.98m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.31 |
| Gross Margin | 57.77% |
| Net Profit Margin | -36.21% |
| Debt/Equity Ratio | 0% |
How did PRE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/15 00:10 |
| End of Day Share Price | 2026/09/15 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prenetics Global Limited is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Ryan Meyers | Lake Street Capital Markets, LLC |
| George Kelly | Roth Capital Partners |